Tuesday, November 5, 2024
HomeTagsZhimeng Biopharma

Zhimeng Biopharma

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics